A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-Label Long Term Extension Safety Study
Sponsor: Bellerophon
Listed as NCT03727451, this PHASE2 trial focuses on Pulmonary Fibrosis and Pulmonary Hypertension and remains completed. Sponsored by Bellerophon, it has been updated 15 times since 2019, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Mar 2022 [monthly]
Recruiting PHASE2
▶ Show 10 earlier versions
-
Feb 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bellerophon
For direct contact, visit the study record on ClinicalTrials.gov .